Overview

NCI Definition: A usually painless malignant tumor that arises from adipose tissue. Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes. Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma. The metastatic potential is higher in less differentiated tumors. [1]

Liposarcomas most frequently harbor alterations in MDM2, CDK4, GLI1, TP53, and TNFAIP3 [2].

Most Commonly Altered Genes in Liposarcoma

MDM2 Amplification, CDK4 Amplification, GLI1 Amplification, TNFAIP3 Amplification, and TP53 Mutation are the most common alterations in liposarcoma [2].

Top Alterations in Liposarcoma

Biomarker-Directed Therapies

Significant Genes in Liposarcoma

AKT1 +

AKT2 +

AKT3 +

CDK4 +

CRKL +

DDIT3 +

EGFR +

ERBB2 +

IRS2 +

KIT +

MET +

MLH1 +

MLH3 +

MSH2 +

MSH3 +

MSH6 +

MTOR +

MYCN +

PDGFRA +

PIK3CA +

PIK3CG +

PIK3R1 +

PIK3R2 +

PMS1 +

PMS2 +

PTEN +

RICTOR +

RNF43 +

RPTOR +

TSC1 +

TSC2 +

Disease Details

Synonyms
LIPOSARCOMA, MALIGNANT, Liposarcoma Not Otherwise Specified, Soft tissue liposarcoma
Parent(s)
Sarcoma
Children
Well Differentiated Liposarcoma, Esophageal Liposarcoma, Childhood Liposarcoma, Atypical Lipomatous Tumor, Myxoid Liposarcoma, Kidney Liposarcoma, Pleomorphic Liposarcoma, Round Cell Liposarcoma, Breast Liposarcoma, Gastric Liposarcoma, Laryngeal Liposarcoma, Mixed Liposarcoma, Vulvar Liposarcoma, Fibroblastic Liposarcoma, Adult Liposarcoma, Dedifferentiated Liposarcoma, Bone Liposarcoma, Mediastinal Liposarcoma, Ovarian Liposarcoma, Intracranial Liposarcoma, and Cutaneous Liposarcoma
OncoTree Name
Liposarcoma
OncoTree Code
LIPO

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.